IntelliNIPT™ - Intelligenetic
IntelliNIPT™
The IntelliNIPT™ is a painless, blood draw–based test that enables the detection of Down syndrome, Edwards syndrome, Patau syndrome, as well as all other chromosomal trisomies, even in the early stages of pregnancy.
The NIPT provided by Intelligenetic has been renewed: the Verifi® test has been replaced by IntelliNIPT™.
The new IntelliNIPT™ test continues to be based on technology from Illumina, the provider behind the Verifi® test.
IntelliNIPT™
The IntelliNIPT™ is a painless, blood draw–based test that enables the detection of Down syndrome, Edwards syndrome, Patau syndrome, as well as all other chromosomal trisomies, even in the early stages of pregnancy.
The NIPT provided by Intelligenetic has been renewed: the Verifi® test has been replaced by IntelliNIPT™. The new IntelliNIPT™ test continues to be based on technology from Illumina, the provider behind the Verifi® test.
The time has come for expanded NIPT
Accurate results within days
When waiting for important news, every minute feels like an eternity. We understand this, so our entire team works to ensure your sample reaches the laboratory as quickly as possible to begin testing. Thanks to precisely coordinated processes, results are usually available within 3 working days of the sample’s arrival at the lab.
High-confidence detection of chromosomal abnormalities
-
IntelliNIPT™
Next-generation laboratory
- All IntelliNIPT™ genetic testing is carried out in our partner Veritas International’s European laboratory under the strictest safety protocols. Our scientists are recognized worldwide as pioneers in genetic testing.
- The new laboratory in Barcelona was inaugurated in the second half of 2020 and uses the most advanced technology from Illumina, the global leader in sequencing.
- The laboratory’s technical team is led by Dr. Vincenzo Cirigliano, an internationally recognized pioneer in developing and introducing innovative molecular tests in prenatal diagnostics into clinical practice, including rapid aneuploidy diagnosis with QF-PCR, as well as the introduction of microarrays and non-invasive prenatal tests (NIPT).
-
TEST PROCESS
The IntelliNIPT™ prenatal test measures the amount of genetic material (DNA) in the blood sample taken and determines whether the genetic material of the mother and the fetus contains too many or too few chromosomes.
Missing or extra chromosomes are called aneuploidies. These can be associated with conditions such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), or trisomy 13 (Patau syndrome). The test can also identify other disorders caused by missing or extra chromosomes, including sex chromosome abnormalities (X or Y).
-
dfg
-
IntelliNIPT™ – Advanced Prenatal Screening
dfg
Frequently Asked Questions
By deciding to have a fetal test to make sure that your unborn child is not at risk of Down syndrome, Edwards syndrome, or Patau syndrome, you are acting as a responsible parent. The tests on the market today, often referred to simply as Down syndrome tests, are similar in many ways, but they also differ in at least this many factors. Everyone claims to know the most about their own, so before choosing, compare them based on the aspects that are important to you. To help you make a responsible decision, we have compiled a list of questions and answers that contain the most frequently asked questions about IntelliNIPT.
IntelliNIPT™ is a new-generation non-invasive prenatal test (NIPT) – a screening method for pregnant women to assess the risk that their baby might be born with certain chromosomal abnormalities, without the miscarriage risk associated with invasive procedures such as chorionic villus sampling or amniocentesis.
In 2013, Intelligenetic partnered to bring the Verifi® test to Hungary. The Verifi® test was developed by Verinata Health, a subsidiary of Illumina®, one of the world’s largest genetic research companies. Illumina® is a leading developer, manufacturer, and distributor of life science tools and integrated systems for large-scale genetic variation and function analysis. These systems enable studies that were unimaginable a few years ago and bring us closer to personalized medicine. IntelliNIPT™ was inspired by Illumina®’s Verifi® test, and its technology is based on the Illumina® VeriSeq™ NIPT Solution v2.
- For all pregnant women from the 10 weeks of pregnancy onwards.
- Can be performed for singleton and twin pregnancies.
- Suitable for pregnancies conceived via assisted reproduction, including donor gametes.
Thanks to continuous innovation, IntelliNIPT™ can detect the tested chromosomal abnormalities with high certainty from 10 weeks of gestation and can be performed no later than the 20th week of pregnancy.
IntelliNIPT™ genetic testing is performed in the European laboratory of our partner, Veritas International, in Barcelona, according to the strictest safety protocols.
When you're waiting for important news, every minute seems like an eternity. We know this, so all of our staff work to ensure that the sample is delivered to the lab as quickly as possible and the test can begin. As a result of precisely coordinated processes, the test results are usually ready within 3 working days after the sample arrives at the lab.
IntelliNIPT™ tests for the most common chromosomal abnormalities: Down's, Edwards' and Patau's syndromes (trisomies 21, 18 and 13) as well as changes in the sex chromosomes. In addition, we offer GenomeScreen, which extends the analysis and provides a more comprehensive screening that includes:
- Genetic abnormalities affect only a portion of the chromosomes. Fetal DNA analysis can detect large DNA deletions (the loss of part of the genetic material) and duplications (the duplication of part of the genetic material), which can cause disorders such as delayed cognitive development.
- Abnormalities in all chromosomes. This option allows the analysis to be extended to other fetal chromosomes, including the examination of rare chromosome number abnormalities, which are mostly associated with fetal loss or other structural abnormalities.
Chromosomal trisomy occurs when there are three chromosomes instead of two in the chromosome set.
The most common trisomy is trisomy of chromosome 21. This causes Down syndrome, which is the most common genetic disease associated with mental retardation and physical abnormalities. In Hungary, its birth incidence is 1:600, which means that one fetus out of every 600 births is expected to have Down syndrome.
The second most common chromosomal abnormality is Edwards syndrome, which is trisomy of chromosome 18, meaning there are three copies of chromosome 18 instead of two. Its birth frequency is 1:7000, however, a significant proportion of fetuses die during pregnancy and most infants born with Edwards syndrome do not even reach the age of one year.
Trisomy 13 is called Patau's disease, where there are three copies of chromosome 13 instead of two. Its frequency is 1:10,000, or one in 10,000 births, but a very small percentage of fetuses are born alive, most of them die during pregnancy.
Fetal chromosomal abnormalities are not limited to the three common trisomies (21, 18, 13). Why should screening always be limited to these?
Prenatal screening for trisomy 21, 18, and 13 has been available for over 30 years. The narrow focus on the three aneuploidies was due to testing limitations, not because they were the only known chromosomal abnormalities.
IntelliNIPT™ GenomeScreen expands the analysis and provides a more comprehensive screening that includes:
- Genetic abnormalities affect only a subset of chromosomes. Fetal DNA analysis can detect large DNA deletions (the loss of part of the genetic material) and duplications (the duplication of part of the genetic material), which can cause abnormalities such as delayed cognitive development.
- Abnormalities in all chromosomes. This option allows the analysis to be extended to other fetal chromosomes, including rare chromosome number abnormalities that are usually associated with fetal loss or other structural abnormalities.
Yes. In twin pregnancies, trisomies 21, 18, and 13 are screened as standard. The presence of the Y chromosome can also be detected to determine if at least one twin is male. In twin pregnancies, numerical abnormalities and large CNVs (>7 Mb) can be assessed for all autosomes, but not for sex chromosomes.
Not available for triplet or quadruplet pregnancies.
The VeriSeq™ NIPT Solution v2 shows high sensitivity and specificity for detecting trisomies 21, 18, and 13 in singleton pregnancies during primary screening (excluding known mosaics). Source: VeriSeq™ NIPT Solution v2 package insert, April 2020. Data on file, Illumina, Inc. 2020.
IntelliNIPT™ determines the risk of fetal chromosomal abnormalities. Results may be consistent with the “absence” of abnormalities in the chromosomes analyzed (low risk) or the “presence” of an abnormality (high risk). Depending on the option requested, the abnormalities reported may include: monosomies, trisomies, multiple aneuploidies, partial deletions or duplications greater than 7 Mb. We also report the percentage of fetal DNA (fetal fraction). Depending on the option requested, the test results may include the sex of the fetus. If you do not wish to know, your healthcare provider can exclude this information by selecting the option that allows it.
LIMITATIONS OF THE TEST
IntelliNIPT™ is a screening test and, as such, has limitations, including the possibility of false-positive and false-negative results. This means that chromosomal abnormalities may be present even if you receive a “low-risk” result (false negative), or you may receive a “high-risk” result for a certain abnormality that is not actually present (false positive).
The test is not designed to detect triploidy, translocations, or mosaic aneuploidies. A result consistent with the absence of abnormalities does not guarantee a healthy pregnancy or fetus and does not exclude the possibility of other genetic changes not analyzed by this test.
Due to the origin of the tested DNA, the results may reflect the chromosomal status of the placenta (confined placental mosaicism), maternal chromosomal abnormalities, or abnormalities in an undiagnosed, non-developing co-twin (vanishing twin syndrome).
The test is not intended to provide information about your own health, but in rare cases it may do so — for example, in the presence of sex chromosome aneuploidies or previously undiagnosed benign or malignant tumors.
In twin pregnancies, individual risk for each fetus cannot be determined for either sex chromosome aneuploidies or other chromosomal abnormalities. If a Y chromosome is detected, it cannot be determined whether only one fetus is male or both. In cases of vanishing twin, results may reflect the chromosomal profile of the non-developing fetus, which can increase the likelihood of false-positive or false-negative results.
As a screening test, irreversible clinical decisions must not be made based solely on these results. Any result indicating abnormalities must be confirmed by invasive prenatal diagnostic testing (e.g., amniocentesis), which allows for the analysis of fetal-derived DNA.
Some rare aneuploidies may occur only in mosaic form; the clinical consequences depend on the affected chromosome and cannot be predicted before birth. All results must be interpreted in the context of available clinical information by a healthcare professional, who can assess the implications and recommend further monitoring.
The test fee can be reimbursed through a health insurance fund. We currently have agreements with the following providers:
- PRÉMIUM Health Fund
- OTP Health Fund
- TEMPO Health Fund
- VITAMIN Health Fund
- PATIKA Health Fund
- ÚJ PILLÉR Health Fund
- DIMENZIÓ Health Fund
- VASUTAS Health Fund
- MKB Health & Self-Help Fund
- GENERALI Health & Self-Help Fund
- ALLIANZ Hungária Health & Self-Help Fund
(If your health fund is not listed above, please contact us.)
Yes. The test is CE-IVD marked and compliant with the In Vitro Diagnostic Regulation (IVDR).
You can register for the test and pre-test specialist consultation directly: +36 1 700 1303 Or via the BOOKING menu on our website.
Outside office hours, please email
At your appointment, 10 ml of blood will be taken and sent immediately to our diagnostic center. The test takes 5–7 working days, and results are sent to your genetic counseling physician, who will explain both the results and their significance.
IntelliNIPT™ – Fetal DNA testing without miscarriage risk
-
IntelliNIPT™
Fetal DNA testing without miscarriage riskThe IntelliNIPT™ prenatal test measures the amount of genetic material (DNA) in the blood sample taken and determines whether the genetic material of the mother and fetus contains too many or too few chromosomes. Missing or extra chromosomes are referred to as aneuploidies. These can be associated with conditions such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), or trisomy 13 (Patau syndrome).
The test can also identify other conditions caused by missing or extra chromosomes or sex chromosomes (X or Y).
-
Amniocentesis
A test that carries a risk of miscarriage.
When it comes to Down syndrome screening, there are different opinions about methods. While few dispute the need for screening, there are widely differing views about the path to results and the technology used.
Through the IntelliNIPT™ test, we aim to provide an objective overview of available options, presenting our test as a safe alternative to invasive methods. Unlike amniocentesis, which can cause discomfort and, in some cases, miscarriage in otherwise healthy pregnancies, our test is non-invasive and painless.
IntelliNIPT™ – Advanced, efficient, and precise technology.
- The VeriSeq™ NIPT Solution v2 demonstrates high sensitivity and specificity for detecting trisomies 21, 18, and 13 in singleton pregnancies during primary screening (excluding known mosaics). Source: VeriSeq™ NIPT Solution v2 package insert, April 2020. Data on file, Illumina, Inc. 2020.
Results usually within 5 working days.
Chromosomes, Trisomy
What are the benefits of the expanded IntelliNIPT™
Fetal chromosomal abnormalities are not limited to the three common trisomies (21, 18, 13). Why should screening always be limited to these? Prenatal screening for trisomies 21, 18, and 13 has been available for more than 30 years. The narrow focus on these three aneuploidies was due to the limitations of testing technology — not because these were the only known chromosomal abnormalities.
The IntelliNIPT™ GenomeScreen expands the analysis, providing more comprehensive screening, including:
<!-- Event snippet for Időpontfoglalás - IntelliNIPT conversion page In your html page, add the snippet and call gtag_report_conversion when someone clicks on the chosen link or button. --> <script> function gtag_report_conversion(url) { var callback = function () { if (typeof(url) != 'undefined') { window.location = url; } }; gtag('event', 'conversion', { 'send_to': 'AW-10946619005/g72PCMnm-c8DEP3M4OMo', 'event_callback': callback }); return false; } </script>